• Biopharma integration growth: Reported profit increased fourfold following the integration of the biosimilars and generics businesses, driven by robust top-line revenue growth across both segments and lower financing expenses.
• Research services turnaround: Syngene, representing approximately 17% of consolidated revenues, is undergoing a leadership-led rebuilding phase after a weak quarter, with management expecting a turnaround in the second half of the fiscal year.
• Interest cost reduction: Quarterly interest costs declined nearly 22% from around 280 crore to 210 crore rupees, keeping the company on track to achieve its guided 300 crore rupee full-year interest expense reduction.
• Geographic revenue mix: Strong biosimilar sales increased North America's revenue contribution from 40% to 45% during the quarter, while Europe's share fell to 32% and emerging markets contributed 23%.
• R&D and margins: R&D investments will remain stable at roughly 7% of revenues, with new biosimilar launches expected to counter legacy product price erosion and sustain mid-20s EBITDA margins.